Dapagliflozin
Cross-source consensus on Dapagliflozin from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Benefits
Dosage & preparation
Other
Highlighted claims
- Dapagliflozin belongs to the SGLT2 inhibitor drug class, which is recognised for cardioprotective and nephroprotective effects in chronic conditions. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- The 10 mg dapagliflozin dose is based on recommended chronic-use dosing for approved indications. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- The trial’s central hypothesis is that dapagliflozin may improve long-term outcomes by preventing progression of cardiovascular and renal injury or mitigating cardiovascular consequences of critical illness. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- A positive DAPA-ICU result would support a readily deployable strategy because dapagliflozin is widely available and has an established safety profile. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)